SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending after issuing weaker-than-expected revenue guidance for the current quarter and fiscal year, despite a strong earnings beat, intensifying investor concerns that AI is disrupting the traditional software business model. The community is sharply divided, with many viewing the steep selloff as an overreaction and a buying opportunity given the company's cash position, while others remain cautious about AI's long-term impact on the SaaS sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community excitement builds over impending EU approval for its Anktiva therapy and Saudi Arabia's expanding commitment to "all cancers" with IBRX, with many anticipating a significant short squeeze. Investors see the company as deeply undervalued, driven by its innovative immunotherapy's potential for widespread adoption in immune restoration and cancer treatment.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to a striking disconnect between recent strong earnings, profitability, and a $500M share buyback, and an unprecedented streak of red daily candles pushing the stock to historic lows. Community sentiment is fiercely divided on whether this presents a generational buying opportunity fueled by its AI/AR smartglasses vision and a potential short squeeze, or if persistent management issues will continue to suppress its value.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio (RGNX) is trending due to a clinical hold placed on its RGX-121 and RGX-111 gene therapy programs following a potential tumor link with the AAV vector, just days before RGX-121's critical PDUFA date. The community is intensely debating whether an imminent Complete Response Letter or a delay is inevitable, with many expecting significant downside, while others highlight the company's other pipeline assets as the true value drivers.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending following its all-stock acquisition of Valaris, a $5.8 billion deal set to create a combined $17 billion offshore drilling industry leader. The community is actively discussing the potential for a strengthened fleet and significant cost savings to capitalize on an emerging upcycle, though some express concerns over shareholder dilution.

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Valaris Ltd

Valaris is trending following the announcement of its all-stock acquisition by Transocean for approximately $5.8 billion, leading to significant community discussion around the deal's implications for shareholders and warrants. This M&A activity coincides with Valaris securing substantial new drilling contracts and ongoing conversations about a strengthening offshore energy sector.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending amidst divided community sentiment surrounding its recent or anticipated earnings, as investors debate whether growth in AI data center and silicon carbide can outweigh ongoing automotive sector weakness and margin pressures. The company's partnership with NVIDIA and a large share repurchase program are key discussion points fueling both bullish and bearish perspectives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2030 Earnings Forecast for VYGR Issued By HC Wainwright

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on...

Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below Fifty Day Moving Average - What's Next?

Voyager Therapeutics (NASDAQ:VYGR) Stock Passes Below 50-Day Moving Average - Time to Sell...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat reports. One investment...

Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below Fifty Day Moving Average - Time to Sell?

Voyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

Voyager Therapeutics, Inc. $VYGR Shares Sold by Armistice Capital LLC

Armistice Capital LLC lowered its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 11.7% in the second quarter, according to the company in its most recent disclosure with the...

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat reports. One...

Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below Fifty Day Moving Average - Here's What Happened

FY2025 Earnings Forecast for VYGR Issued By HC Wainwright

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at HC Wainwright dropped their FY2025 EPS estimates for Voyager Therapeutics in a report issued on Wednesday, November 12th...

What is Wedbush's Estimate for VYGR FY2025 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Stock analysts at Wedbush lifted their FY2025 earnings per share estimates for shares of Voyager Therapeutics in a research report issued to...

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Voyager Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$3.71
Prev Close	$3.68
Open	$3.62
Dividend Yield	0.00%
50-Day Moving Average	$4.04
Beta	1.43
Avg. Volume	667,654.10
PE Ratio	-1.70

52-Week High	$5.55
52-Week Low	$2.65
Market Capitalization	$204.61M
EPS (Annual)	-$1.13
Price to Book	0.93
Revenue Per Employee	$465,122.09
Enterprise Value/EBITDA	N/A

VYGR
Voyager Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VYGR News

VYGRVoyager Therapeutics Inc